Alexandra Barkóczi , Zita Képes , Judit P. Szabó , Renáta Adél Dienes , Péter Kálmán Károlyi , Tamás Papp , Ibolya Kálmán-Szabó , Tamás Sass , Gábor Opposits , István Kertész , István Hajdu , György Trencsényi , Ádám Deák
{"title":"转移和血管生成:肝细胞癌(He/De)肿瘤模型的临床前PET研究。","authors":"Alexandra Barkóczi , Zita Képes , Judit P. Szabó , Renáta Adél Dienes , Péter Kálmán Károlyi , Tamás Papp , Ibolya Kálmán-Szabó , Tamás Sass , Gábor Opposits , István Kertész , István Hajdu , György Trencsényi , Ádám Deák","doi":"10.1016/j.ejps.2025.107211","DOIUrl":null,"url":null,"abstract":"<div><div>The use of animal models to study tumorigenesis and metastatic spread seems crucial to discover novel diagnostic and therapeutic targets that inhibit tumor development and progression. In this study a preclinical metastasis model of hepatocellular carcinoma (He/De) was established to explore metastases formation and related angiogenic processes using positron emission tomography (PET) and angiogenesis specific radiopharmaceuticals. Approximately 8 ± 1 days after the subrenal capsule assay-based generation of the primary, secondary and tertiary transplanted metastatic He/De tumors in Fischer-344 rats, we used [<sup>18</sup>F]FDG, [<sup>68</sup>Ga]Ga-NOTA-c(NGR) and [<sup>68</sup>Ga]Ga-NODAGA-[c(RGD)]<sub>2</sub> for the <em>in vivo</em> PET imaging of tumor development and angiogenesis. [<sup>18</sup>F]FDG displayed the highest level of radioactivity among all investigated tracers. This pattern was consistent across all neoplastic lesions in each of the three transplantations. Comparing the two <sup>68</sup>Ga-labelled probes, the NGR compound showed significantly higher accumulation in the subrenally growing primary/secondary/tertiary He/De tumors <em>(p</em> <em>≤</em> <em>0.05)</em> and related parathymic lymph node metastases (PTLNs, <em>p</em> <em>≤</em> <em>0.01</em>) that could indicate higher expression level for aminopeptidase N/CD13 than for RGD-binding α<sub>v</sub>β<sub>3</sub> integrin. Progressive increase in the [<sup>18</sup>F]FDG, [<sup>68</sup>Ga]Ga-NOTA-c(NGR) and [<sup>68</sup>Ga]Ga-NODAGA-[c(RGD)]<sub>2</sub> uptakes of both the subrenally growing He/De tumors and the PTLNs during the serial transplantations may imply increasing aggressivity. Overall, the currently developed experimental system provides a feasible platform for further investigation of metastatic spread.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"212 ","pages":"Article 107211"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metastasis and angiogenesis: preclinical PET study on hepatocellular carcinoma (He/De) tumor models\",\"authors\":\"Alexandra Barkóczi , Zita Képes , Judit P. Szabó , Renáta Adél Dienes , Péter Kálmán Károlyi , Tamás Papp , Ibolya Kálmán-Szabó , Tamás Sass , Gábor Opposits , István Kertész , István Hajdu , György Trencsényi , Ádám Deák\",\"doi\":\"10.1016/j.ejps.2025.107211\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The use of animal models to study tumorigenesis and metastatic spread seems crucial to discover novel diagnostic and therapeutic targets that inhibit tumor development and progression. In this study a preclinical metastasis model of hepatocellular carcinoma (He/De) was established to explore metastases formation and related angiogenic processes using positron emission tomography (PET) and angiogenesis specific radiopharmaceuticals. Approximately 8 ± 1 days after the subrenal capsule assay-based generation of the primary, secondary and tertiary transplanted metastatic He/De tumors in Fischer-344 rats, we used [<sup>18</sup>F]FDG, [<sup>68</sup>Ga]Ga-NOTA-c(NGR) and [<sup>68</sup>Ga]Ga-NODAGA-[c(RGD)]<sub>2</sub> for the <em>in vivo</em> PET imaging of tumor development and angiogenesis. [<sup>18</sup>F]FDG displayed the highest level of radioactivity among all investigated tracers. This pattern was consistent across all neoplastic lesions in each of the three transplantations. Comparing the two <sup>68</sup>Ga-labelled probes, the NGR compound showed significantly higher accumulation in the subrenally growing primary/secondary/tertiary He/De tumors <em>(p</em> <em>≤</em> <em>0.05)</em> and related parathymic lymph node metastases (PTLNs, <em>p</em> <em>≤</em> <em>0.01</em>) that could indicate higher expression level for aminopeptidase N/CD13 than for RGD-binding α<sub>v</sub>β<sub>3</sub> integrin. Progressive increase in the [<sup>18</sup>F]FDG, [<sup>68</sup>Ga]Ga-NOTA-c(NGR) and [<sup>68</sup>Ga]Ga-NODAGA-[c(RGD)]<sub>2</sub> uptakes of both the subrenally growing He/De tumors and the PTLNs during the serial transplantations may imply increasing aggressivity. Overall, the currently developed experimental system provides a feasible platform for further investigation of metastatic spread.</div></div>\",\"PeriodicalId\":12018,\"journal\":{\"name\":\"European Journal of Pharmaceutical Sciences\",\"volume\":\"212 \",\"pages\":\"Article 107211\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-07-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0928098725002106\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098725002106","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Metastasis and angiogenesis: preclinical PET study on hepatocellular carcinoma (He/De) tumor models
The use of animal models to study tumorigenesis and metastatic spread seems crucial to discover novel diagnostic and therapeutic targets that inhibit tumor development and progression. In this study a preclinical metastasis model of hepatocellular carcinoma (He/De) was established to explore metastases formation and related angiogenic processes using positron emission tomography (PET) and angiogenesis specific radiopharmaceuticals. Approximately 8 ± 1 days after the subrenal capsule assay-based generation of the primary, secondary and tertiary transplanted metastatic He/De tumors in Fischer-344 rats, we used [18F]FDG, [68Ga]Ga-NOTA-c(NGR) and [68Ga]Ga-NODAGA-[c(RGD)]2 for the in vivo PET imaging of tumor development and angiogenesis. [18F]FDG displayed the highest level of radioactivity among all investigated tracers. This pattern was consistent across all neoplastic lesions in each of the three transplantations. Comparing the two 68Ga-labelled probes, the NGR compound showed significantly higher accumulation in the subrenally growing primary/secondary/tertiary He/De tumors (p≤0.05) and related parathymic lymph node metastases (PTLNs, p≤0.01) that could indicate higher expression level for aminopeptidase N/CD13 than for RGD-binding αvβ3 integrin. Progressive increase in the [18F]FDG, [68Ga]Ga-NOTA-c(NGR) and [68Ga]Ga-NODAGA-[c(RGD)]2 uptakes of both the subrenally growing He/De tumors and the PTLNs during the serial transplantations may imply increasing aggressivity. Overall, the currently developed experimental system provides a feasible platform for further investigation of metastatic spread.
期刊介绍:
The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development.
More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making.
Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.